{
  "experiment_id": "aa7227018343fa2a5f6df22ada9bd727",
  "task_name": "narrowing_of_broad_synonyms",
  "task_hash": "fad80e5ef0b6a35a2e224357c530fdf1",
  "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
  "system_instructions": "You are a metadata curation assistant. Your task is to help improve and correct metadata \naccording to the specific instructions provided for each task. Be precise, accurate, and \nfollow the guidelines carefully.\n",
  "temperature": 0.0,
  "thinking": true,
  "timestamp": "2025-11-13T04:13:44.920852",
  "task_result": {
    "task_name": "narrowing_of_broad_synonyms",
    "num_samples": 10,
    "results": [
      {
        "sample_index": 0,
        "input": {
          "diagnosis": "Neurofibromatosis",
          "assay": "DNA sequencing",
          "tumorType": "Neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"Neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (the most common form of neurofibromatosis, consistent with the neurofibroma tumor type)\n\n2. **assay**: Narrowed \"DNA sequencing\" \u2192 \"whole exome sequencing\" (a specific, commonly-used DNA sequencing method in clinical genetics research)\n\n3. **tumorType**: \"Neurofibroma\" remains unchanged as it is already an exact match in the controlled terminology, representing the general category of this tumor type",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3058,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1355
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01RVRpK8wsmA8jJ736CVP9q5",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data, I need to narrow broad synonyms to more specific terms using the exact controlled terminology from the Target Schema.\n\nLet me analyze each field:\n\n1. **diagnosis**: \"Neurofibromatosis\"\n   - This is broad. Looking at the enum values, I can see:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n   - \"Neurofibromatosis\" could refer to NF1 or NF2. The most common form is NF1 (Neurofibromatosis type 1), which accounts for about 96% of cases. Given the context with \"Neurofibroma\" in tumorType (which is most commonly associated with NF1), the most appropriate narrowing would be \"Neurofibromatosis type 1\".\n\n2. **assay**: \"DNA sequencing\"\n   - This is a broad term. Looking at the enum values for specific DNA sequencing methods:\n     - \"whole genome sequencing\"\n     - \"whole exome sequencing\"\n     - \"targeted sequencing\"\n     - \"next generation targeted sequencing\"\n     - \"Sanger sequencing\"\n     - \"bisulfite sequencing\"\n     - \"ERR bisulfite sequencing\"\n     - \"oxBS-seq\"\n     - \"NOMe-seq\"\n   - Without more context, \"whole genome sequencing\" is a common comprehensive DNA sequencing approach that would be a reasonable narrowing of the broad \"DNA sequencing\" term. However, \"whole exome sequencing\" is also very common in clinical/research settings. Given that this is about neurofibromatosis research, whole exome sequencing is frequently used. But \"whole genome sequencing\" is slightly broader and more comprehensive, so it might be the best choice for narrowing \"DNA sequencing\" when we don't have more specific information.\n\n3. **tumorType**: \"Neurofibroma\"\n   - The term is already present in the enum list. However, there are more specific subtypes available.\n   - Considering the context of Neurofibromatosis type 1, \"Plexiform Neurofibroma\" might be the most appropriate specific type, as it's characteristic of NF1 and has clinical significance. I'm analyzing the enum values and need to narrow broad terms to more specific variants. For \"Neurofibromatosis\", I'll specify \"Neurofibromatosis type 1\" since it's the most prevalent form and aligns with the neurofibroma context. With \"DNA sequencing\", I'll select \"whole exome sequencing\" as a precise clinical genetics methodology. The \"Neurofibroma\" term requires careful consideration - while it matches the enum, its subtypes like cutaneous or plexiform neurofibromas offer more precision, though additional clinical context would help definitively select the most appropriate variant.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: Narrowed \"Neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" (the most common form of neurofibromatosis, consistent with the neurofibroma tumor type)\n\n2. **assay**: Narrowed \"DNA sequencing\" \u2192 \"whole exome sequencing\" (a specific, commonly-used DNA sequencing method in clinical genetics research)\n\n3. **tumorType**: \"Neurofibroma\" remains unchanged as it is already an exact match in the controlled terminology, representing the general category of this tumor type"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3058,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1355
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Plexiform Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3058,
          "output_tokens": 1355,
          "total_tokens": 4413
        }
      },
      {
        "sample_index": 1,
        "input": {
          "diagnosis": "NF",
          "assay": "exome sequencing",
          "tumorType": "sarcoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation \"NF\" to the specific diagnosis \"Neurofibromatosis type 1\", which is the most common form of neurofibromatosis.\n\n2. **assay**: \"exome sequencing\" \u2192 \"whole exome sequencing\" - Corrected to use the exact controlled terminology from the schema enum.\n\n3. **tumorType**: \"sarcoma\" \u2192 \"Sarcoma\" - Corrected capitalization to match the exact enum value in the Target Schema.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3052,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1030
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01LanXXtgcZtLpLjVvUfYHBZ",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data, I need to narrow broad synonyms to more specific controlled terminology values from the Target Schema:\n\n1. **diagnosis**: \"NF\" - This is a broad term. Looking at the enum values, I can see:\n   - \"Neurofibromatosis type 1\"\n   - \"NF2-related schwannomatosis\"\n   - Various other specific diagnoses\n   \n   \"NF\" likely stands for Neurofibromatosis. The most common form is Neurofibromatosis type 1 (NF1). However, without more context, \"NF\" could refer to NF1 or NF2. Looking at the schema, \"Neurofibromatosis type 1\" is the exact value in the enum. Since NF1 is the most common form and is listed as \"Neurofibromatosis type 1\" in the schema, that would be the most appropriate specific narrowing.\n\n2. **assay**: \"exome sequencing\" - Looking at the enum values, I can see:\n   - \"whole exome sequencing\"\n   - \"whole genome sequencing\"\n   - \"targeted sequencing\"\n   - \"next generation targeted sequencing\"\n   \n   \"exome sequencing\" is clearly referring to \"whole exome sequencing\" which is the exact term in the schema.\n\n3. **tumorType**: \"sarcoma\" - Looking at the enum values, I can see:\n   - \"Sarcoma\"\n   - \"Malignant Peripheral Nerve Sheath Tumor\"\n   - \"Fibrosarcoma\"\n   \n   Wait, \"Sarcoma\" is actually already in the enum list! But the task says to narrow broad synonyms to more specific terms. \"Sarcoma\" is listed in the enum, so it's a valid value. However, checking the capitalization - the input has \"sarcoma\" (lowercase) while the enum has \"Sarcoma\" (capitalized). \n\nI need to match the exact value from the schema, which is \"Sarcoma\". The instruction asks me to narrow broad terms, but \"Sarcoma\" already exists in the enum. While more specific types like \"Fibrosarcoma\" or \"Malignant Peripheral Nerve Sheath Tumor\" are available, I lack the context to determine which specific subtype applies. I should use the exact controlled terminology value \"Sarcoma\" from the schema.\n\nFor the diagnosis field, \"NF\" is too broad. Between \"Neurofibromatosis type 1\" and \"NF2-related schwannomatosis\", NF1 is more commonly associated with sarcomas, particularly MPNSTs. I'll narrow \"NF\" to \"Neurofibromatosis type 1\" and change \"exome sequencing\" to \"whole exome sequencing\".",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"whole exome sequencing\",\n  \"tumorType\": \"Sarcoma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation \"NF\" to the specific diagnosis \"Neurofibromatosis type 1\", which is the most common form of neurofibromatosis.\n\n2. **assay**: \"exome sequencing\" \u2192 \"whole exome sequencing\" - Corrected to use the exact controlled terminology from the schema enum.\n\n3. **tumorType**: \"sarcoma\" \u2192 \"Sarcoma\" - Corrected capitalization to match the exact enum value in the Target Schema."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3052,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1030
            }
          }
        },
        "score": 0.6666666666666666,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole exome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3052,
          "output_tokens": 1030,
          "total_tokens": 4082
        }
      },
      {
        "sample_index": 2,
        "input": {
          "diagnosis": "Neurofibromatoses",
          "assay": "assay by high throughput sequencer",
          "tumorType": "Nerve Sheath Neoplasm"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"RNA-seq\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"Neurofibromatoses\" (broad, plural term for the group of conditions) \u2192 \"Neurofibromatosis type 1\" (specific, most common form of neurofibromatosis)\n\n2. **assay**: \"assay by high throughput sequencer\" (broad term for any high-throughput sequencing) \u2192 \"RNA-seq\" (specific next-generation sequencing method, one of the most commonly used sequencing assays)\n\n3. **tumorType**: \"Nerve Sheath Neoplasm\" (broad category for all nerve sheath tumors) \u2192 \"Neurofibroma\" (specific type of nerve sheath tumor most commonly associated with Neurofibromatosis type 1)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3067,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1514
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01ArW3q1tJ5FqS5wBtbmnXZw",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze each field in the input data and narrow it to the appropriate controlled vocabulary term from the Target Schema:\n\n1. **diagnosis**: \"Neurofibromatoses\"\n   - This is a broad term that encompasses multiple specific conditions\n   - Looking at the enum values, I see specific types:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n     - Various types of schwannomatosis\n   - \"Neurofibromatoses\" is the plural broad category that includes NF1, NF2, and schwannomatosis\n   - The most common and well-known form is \"Neurofibromatosis type 1\"\n   - However, without more context, I cannot definitively say if it's NF1 or NF2\n   - Looking at the options, if I must narrow from \"Neurofibromatoses\" (plural/general), the most commonly referenced specific type would be \"Neurofibromatosis type 1\" (which is by far the most common form, affecting about 1 in 3,000 people)\n   - But wait - I should check if there's an \"Unknown\" option since we don't have enough information. Yes, there is \"Unknown\" in the enum.\n   - Actually, looking more carefully, \"Neurofibromatosis type 1\" is the most specific narrowing of \"Neurofibromatoses\" that is most commonly what is meant when using the general term. NF1 is the classic and most common form.\n\n2. **assay**: \"assay by high throughput sequencer\"\n   - This is a broad term for high-throughput sequencing\n   - Looking at the enum values, there are several sequencing options:\n     - \"whole genome sequencing\"\n     - \"whole exome sequencing\"\n     - \"RNA-seq\"\n     - \"targeted sequencing\"\n     - \"next generation targeted sequencing\"\n     - And many other specific sequencing methods\n   - \"RNA-seq\" is probably the most common application for expression studies, though whole genome sequencing is also widely used for DNA analysis. Without knowing if this is DNA or RNA work, I need to consider which is more typical as a default interpretation.\n\nActually, \"whole genome sequencing\" might be the better choice since it's a comprehensive DNA sequencing approach that's commonly used.\n\nFor tumorType \"Nerve Sheath Neoplasm,\" I'm looking at a broad category that encompasses multiple specific tumor types in the enum. The available options include MPNST, Schwannoma, and various Neurofibroma subtypes. Since the diagnosis mentions \"Neurofibromatoses,\" this context suggests the tumor is likely related to that condition.\n\nIn NF1, neurofibromas are the most characteristic nerve sheath tumors, while NF2 typically presents with schwannomas. Given the NF context and the available enum values, \"Neurofibroma\" appears to be the most appropriate narrowing, though I notice there are both general and more specific neurofibroma subtypes available.\n\nReconsidering the diagnosis field: \"Neurofibromatoses\" is plural, referring to the entire group of conditions. The most specific narrowing would be \"Neurofibromatosis type 1\" since it's the most prevalent form.\n\nFor the assay field, \"assay by high throughput sequencer\" is quite broad. I need to identify which specific high-throughput sequencing method would be most appropriate.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"RNA-seq\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"Neurofibromatoses\" (broad, plural term for the group of conditions) \u2192 \"Neurofibromatosis type 1\" (specific, most common form of neurofibromatosis)\n\n2. **assay**: \"assay by high throughput sequencer\" (broad term for any high-throughput sequencing) \u2192 \"RNA-seq\" (specific next-generation sequencing method, one of the most commonly used sequencing assays)\n\n3. **tumorType**: \"Nerve Sheath Neoplasm\" (broad category for all nerve sheath tumors) \u2192 \"Neurofibroma\" (specific type of nerve sheath tumor most commonly associated with Neurofibromatosis type 1)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3067,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1514
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "whole genome sequencing",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3067,
          "output_tokens": 1514,
          "total_tokens": 4581
        }
      },
      {
        "sample_index": 3,
        "input": {
          "diagnosis": "neurocutaneous syndrome",
          "assay": "spectroscopy",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"FTIR spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"neurocutaneous syndrome\" \u2192 \"Unknown\"\n   - \"Neurocutaneous syndrome\" is a broad category that could encompass multiple specific conditions in the schema (e.g., Neurofibromatosis type 1, various types of schwannomatosis). Without additional context to determine which specific condition, \"Unknown\" is the most accurate narrowing.\n\n2. **assay**: \"spectroscopy\" \u2192 \"FTIR spectroscopy\"\n   - \"Spectroscopy\" is a broad term. The schema includes specific spectroscopy methods: \"FTIR spectroscopy\" and \"magnetic resonance spectroscopy\". FTIR spectroscopy is selected as a common analytical technique used in research settings.\n\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\"\n   - Corrected to match the exact capitalization in the controlled terminology enum value.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3052,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1304
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_019QWgkGA8MVcsYgiAr9zFbw",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "I need to narrow broad synonyms in the provided metadata to more specific, precise terms using the exact controlled terminology values from the Target Schema.\n\nLet me analyze each field:\n\n1. **diagnosis**: \"neurocutaneous syndrome\"\n   - This is a broad term. Looking at the enum values, I can see several neurofibromatosis-related conditions which are types of neurocutaneous syndromes:\n     - \"Neurofibromatosis type 1\"\n     - \"NF2-related schwannomatosis\"\n     - \"22q-related schwannomatosis\"\n     - \"LZTR1-related schwannomatosis\"\n     - \"SMARCB1-related schwannomatosis\"\n     - \"Schwannomatosis\"\n     - etc.\n   \n   However, \"neurocutaneous syndrome\" is very broad and could refer to multiple conditions. The most appropriate narrowing would be to something more specific, but without more context, I should probably select \"Unknown\" since we don't have enough information to specify which exact neurocutaneous syndrome this is. Actually, looking at the options again, \"Neurofibromatosis type 1\" is the most common neurocutaneous syndrome in this domain. But wait - I should be careful. The instruction says to narrow broad terms to more specific ones. If the data says \"neurocutaneous syndrome\" but doesn't specify which one, the most honest answer would be \"Unknown\" rather than assuming NF1. Let me reconsider...\n\n   Actually, given that this is about narrowing broad terms, and \"neurocutaneous syndrome\" is indeed broad, I should select the most commonly represented condition in the schema if context suggests it, or \"Unknown\" if truly indeterminate. Given the context of the schema (heavily focused on NF and schwannomatosis conditions), \"Neurofibromatosis type 1\" might be a reasonable narrowing, but \"Unknown\" is safer without more context.\n\n2. **assay**: \"spectroscopy\"\n   I recognize this as a broad analytical technique. The schema provides specific spectroscopy types like FTIR and magnetic resonance spectroscopy. Without precise context, I'll need to choose carefully. FTIR spectroscopy seems more commonly used, but selecting it requires caution. The goal is to narrow the term to a more specific type while avoiding unwarranted assumptions.\n\nIn biological research contexts, both techniques have distinct applications. FTIR spectroscopy enables molecular characterization, while magnetic resonance spectroscopy supports metabolic profiling. Given the medical research setting, I'll select FTIR spectroscopy as the most appropriate narrow term.\n\nFor the tumorType field, I notice a capitalization discrepancy. The current value is lowercase \"unknown\", but the schema requires \"Unknown\" with a capital U. This requires a precise value match.\n\nRegarding the diagnosis, \"neurocutaneous syndrome\" represents a broad category. Without specific details, using \"Unknown\" ensures accuracy and prevents unwarranted assumptions about the precise condition.\n\nFor the spectroscopy method, \"FTIR spectroscopy\" provides a precise specification that narrows the original broad term. The capitalization for \"Unknown\" in tumorType aligns with the exact enum requirement.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"FTIR spectroscopy\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"neurocutaneous syndrome\" \u2192 \"Unknown\"\n   - \"Neurocutaneous syndrome\" is a broad category that could encompass multiple specific conditions in the schema (e.g., Neurofibromatosis type 1, various types of schwannomatosis). Without additional context to determine which specific condition, \"Unknown\" is the most accurate narrowing.\n\n2. **assay**: \"spectroscopy\" \u2192 \"FTIR spectroscopy\"\n   - \"Spectroscopy\" is a broad term. The schema includes specific spectroscopy methods: \"FTIR spectroscopy\" and \"magnetic resonance spectroscopy\". FTIR spectroscopy is selected as a common analytical technique used in research settings.\n\n3. **tumorType**: \"unknown\" \u2192 \"Unknown\"\n   - Corrected to match the exact capitalization in the controlled terminology enum value."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3052,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1304
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 3052,
          "output_tokens": 1304,
          "total_tokens": 4356
        }
      },
      {
        "sample_index": 4,
        "input": {
          "diagnosis": "Not Applicable",
          "assay": "immunoassay",
          "tumorType": "neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Changes made:**\n- **diagnosis**: No change - \"Not Applicable\" already matches the exact controlled terminology\n- **assay**: No change - \"immunoassay\" is already in the controlled vocabulary as an exact match\n- **tumorType**: Corrected capitalization from \"neurofibroma\" to \"Neurofibroma\" to match the exact controlled terminology in the Target Schema\n\nNote: While \"Neurofibroma\" is a general term and more specific subtypes exist in the schema (such as \"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\", etc.), without additional context to determine the specific subtype, the general term \"Neurofibroma\" from the controlled vocabulary is the appropriate match.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3054,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1170
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_013tjnCuQzXTNQSW2UNfgtZU",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and the target schema to narrow the broad synonyms:\n\nInput data:\n- diagnosis: \"Not Applicable\"\n- assay: \"immunoassay\"\n- tumorType: \"neurofibroma\"\n\nLooking at the Target Schema:\n\n1. **diagnosis**: \"Not Applicable\"\n   - This is already an exact match in the enum values. No change needed.\n\n2. **assay**: \"immunoassay\"\n   - This is a broad term. Looking at the enum, I can see more specific immunoassay types:\n     - \"immunocytochemistry\"\n     - \"immunofluorescence\"\n     - \"immunohistochemistry\"\n     - \"ELISA\"\n   - Wait, \"immunoassay\" itself IS in the enum list! Let me check again...\n   - Yes, \"immunoassay\" is in the enum list. So this is already a valid controlled term.\n   - However, the task is to \"narrow broad synonyms\" - so if \"immunoassay\" is considered broad, I should narrow it to a more specific type.\n   - But the instructions say \"you must use the exact controlled terminology values from the Target Schema\" and \"all values must match the controlled terminology in the Target Schema\"\n   - \"immunoassay\" is already in the schema, but the task is about narrowing BROAD terms to more specific ones.\n   - Looking at the specific immunoassay types available: ELISA, immunocytochemistry, immunofluorescence, immunohistochemistry\n   - Without more context about what type of immunoassay was performed, I cannot definitively choose. However, \"immunoassay\" is listed in the enum, so it's a valid value.\n   - Actually, rereading the instructions: \"The input data contains metadata entries with broad, general terms that should be narrowed to more specific, precise terms.\"\n   - So if \"immunoassay\" is broad, I need to narrow it. But I don't have context to know which specific type. Let me reconsider...\n   - The key is: if the value is ALREADY specific enough and matches the schema exactly, keep it. If it's a variation or synonym not in the schema, then map it to the closest match.\n   - \"immunoassay\" appears in the enum list exactly, so it's already using controlled terminology. It is a broad term, but it's in the allowed list.\n\n3. **tumorType**: \"neurofibroma\"\n   - I'll continue analyzing the tumor type in the next step of my investigation.\n   - Capitalization and exact schema matching are critical for compliance.\n   - I'll adjust \"neurofibroma\" to \"Neurofibroma\" to align with controlled terminology.\n   - Without specific details, I'll use the general term from the enum list.\n   - Confirmed adjustments for diagnosis, assay, and tumor type to match exact schema requirements.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Not Applicable\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Changes made:**\n- **diagnosis**: No change - \"Not Applicable\" already matches the exact controlled terminology\n- **assay**: No change - \"immunoassay\" is already in the controlled vocabulary as an exact match\n- **tumorType**: Corrected capitalization from \"neurofibroma\" to \"Neurofibroma\" to match the exact controlled terminology in the Target Schema\n\nNote: While \"Neurofibroma\" is a general term and more specific subtypes exist in the schema (such as \"Cutaneous Neurofibroma\", \"Plexiform Neurofibroma\", etc.), without additional context to determine the specific subtype, the general term \"Neurofibroma\" from the controlled vocabulary is the appropriate match."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3054,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1170
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Not Applicable",
          "assay": "immunohistochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3054,
          "output_tokens": 1170,
          "total_tokens": 4224
        }
      },
      {
        "sample_index": 5,
        "input": {
          "diagnosis": "neurofibromatosis",
          "assay": "plate based reporter assay",
          "tumorType": "benign neurofibroma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"massively parallel reporter assay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of narrowing:**\n\n1. **diagnosis**: \"neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad umbrella term to the most common specific type of neurofibromatosis\n\n2. **assay**: \"plate based reporter assay\" \u2192 \"massively parallel reporter assay\" - Narrowed to the specific reporter assay methodology available in the controlled vocabulary\n\n3. **tumorType**: \"benign neurofibroma\" \u2192 \"Neurofibroma\" - Narrowed to the precise controlled terminology term for this tumor type (note: \"Neurofibroma\" in the schema refers to benign neurofibromas, as distinct from more specific subtypes also listed)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3060,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 968
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01DbQrR4NeFdD1tTdcHbqRhD",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow each broad term to match the exact controlled terminology in the Target Schema.\n\n1. **diagnosis**: \"neurofibromatosis\"\n   - This is a broad term. Looking at the enum values, I can see:\n     - \"Neurofibromatosis type 1\" - this is the most common type and the most specific match\n   - Since \"neurofibromatosis\" without a type specification is broad, and the most common form is NF1 (Neurofibromatosis type 1), I should narrow it to \"Neurofibromatosis type 1\"\n\n2. **assay**: \"plate based reporter assay\"\n   - Looking through the assay enum values, I need to find the most specific match:\n     - \"massively parallel reporter assay\" - this is a reporter assay that could be plate-based\n   - This seems like the most appropriate narrowing for a \"plate based reporter assay\"\n\n3. **tumorType**: \"benign neurofibroma\"\n   - This is broad. Looking at the enum values, there are several specific types of neurofibromas:\n     - \"Neurofibroma\" - this is the general term\n     - \"Cutaneous Neurofibroma\"\n     - \"Cellular Neurofibroma\"\n     - \"Diffuse Infiltrating Neurofibroma\"\n     - \"Localized Neurofibroma\"\n     - \"Massive Soft Tissue Neurofibroma\"\n     - \"Neurofibroma with Degenerative Atypia\"\n     - \"Nodular Neurofibroma\"\n     - \"Plexiform Neurofibroma\"\n     - \"Subcutaneous Neurofibroma\"\n   \n   Since \"benign neurofibroma\" is broad and doesn't specify which type, the most appropriate narrowing would be to \"Neurofibroma\" which is the general term for benign neurofibromas in the controlled vocabulary. However, if we need to be more specific, we could choose \"Localized Neurofibroma\" or \"Cutaneous Neurofibroma\" as these are common benign forms. But since we don't have more context, \"Neurofibroma\" seems most appropriate as it's the standard term for benign neurofibroma in the schema.\n   \nI'm refining my approach to ensure precise terminology mapping. The key is selecting the most specific controlled term that accurately represents the original broad input while maintaining the essential meaning.\n\nFor neurofibroma classifications, I'll select the most precise descriptor that fits the schema's recommended nomenclature. This means choosing \"Neurofibroma\" as the targeted, specific term.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"massively parallel reporter assay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Explanation of narrowing:**\n\n1. **diagnosis**: \"neurofibromatosis\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad umbrella term to the most common specific type of neurofibromatosis\n\n2. **assay**: \"plate based reporter assay\" \u2192 \"massively parallel reporter assay\" - Narrowed to the specific reporter assay methodology available in the controlled vocabulary\n\n3. **tumorType**: \"benign neurofibroma\" \u2192 \"Neurofibroma\" - Narrowed to the precise controlled terminology term for this tumor type (note: \"Neurofibroma\" in the schema refers to benign neurofibromas, as distinct from more specific subtypes also listed)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3060,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 968
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "cell viability assay",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3060,
          "output_tokens": 968,
          "total_tokens": 4028
        }
      },
      {
        "sample_index": 6,
        "input": {
          "diagnosis": "RASopathy",
          "assay": "immunoassay",
          "tumorType": "NFIB"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"RASopathy\" \u2192 \"Neurofibromatosis type 1\" - RASopathy is a broad category of genetic disorders affecting the RAS/MAPK pathway. Narrowed to Neurofibromatosis type 1, which is the most common RASopathy and is consistent with the neurofibroma tumor type context.\n\n2. **assay**: \"immunoassay\" - Kept as is. While this is a general category, it is an exact match in the controlled terminology enum. Without additional context to determine the specific immunoassay type (ELISA, immunohistochemistry, etc.), this remains the most accurate value.\n\n3. **tumorType**: \"NFIB\" \u2192 \"Neurofibroma\" - NFIB is not in the controlled terminology and appears to be an abbreviation or informal term. Narrowed to \"Neurofibroma\", which is the appropriate specific tumor type term from the schema that aligns with neurofibromatosis.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3055,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1491
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01WCcgCxmfPAyxjsQfUJDhEX",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data, I need to narrow these broad terms to more specific ones from the controlled terminology:\n\n1. \"diagnosis\": \"RASopathy\" - This is a broad term referring to a group of genetic disorders caused by mutations in the RAS/MAPK pathway. Looking at the enum values in the schema, I can see several specific RASopathies:\n   - \"Neurofibromatosis type 1\" (NF1 is a RASopathy)\n   - \"Noonan Syndrome\" (is a RASopathy)\n   \n   However, without more specific context, I cannot definitively narrow this to one specific diagnosis. The most appropriate action would be to either use \"Unknown\" if we truly don't know, or keep it as one of the more general options. But wait - looking at the schema, there's no \"RASopathy\" in the enum, so I need to pick from what's available. Given the context of the other fields (NFIB tumor type suggests neurofibromatosis), \"Neurofibromatosis type 1\" seems most likely. But I should be careful - the user said to narrow to more specific terms. Since RASopathy includes NF1, Noonan, and others, and we have \"NFIB\" in tumorType which suggests neurofibromatosis, I'll narrow to \"Neurofibromatosis type 1\".\n\n2. \"assay\": \"immunoassay\" - This is already in the enum list exactly as written. However, the task is to narrow broad terms. \"immunoassay\" is a general category that could include more specific types like:\n   - \"ELISA\"\n   - \"immunocytochemistry\"\n   - \"immunofluorescence\"\n   - \"immunohistochemistry\"\n   - \"reverse phase protein array\"\n   \n   Without more context about what specific type of immunoassay was used, I cannot definitively narrow this. But wait - \"immunoassay\" IS in the enum list, so it's a valid value. \n\nI'm hesitant to change the immunoassay term without clear additional information. While the instruction is to narrow broad synonyms, I lack specific details to confidently select a more precise immunoassay type. The safest approach is to maintain the current \"immunoassay\" designation.\n\nFor the tumor type, I recognize \"NFIB\" isn't standard. Given the NF1 context, \"Neurofibroma\" seems the most appropriate choice - it's specific enough to capture the underlying condition while remaining precise within the available options.\n\nCarefully reviewing the metadata requirements, I'll focus on narrowing broad terms to controlled vocabulary. The RASopathy clearly maps to \"Neurofibromatosis type 1\", which provides a more exact diagnostic description. The immunoassay term remains appropriately general without additional context.\n\nFor NFIB, the most precise interpretation is \"Neurofibroma\", aligning with the genetic and tumor context. This approach ensures maximum specificity while respecting the target schema's controlled terminology.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"immunoassay\",\n  \"tumorType\": \"Neurofibroma\"\n}\n```\n\n**Corrections made:**\n\n1. **diagnosis**: \"RASopathy\" \u2192 \"Neurofibromatosis type 1\" - RASopathy is a broad category of genetic disorders affecting the RAS/MAPK pathway. Narrowed to Neurofibromatosis type 1, which is the most common RASopathy and is consistent with the neurofibroma tumor type context.\n\n2. **assay**: \"immunoassay\" - Kept as is. While this is a general category, it is an exact match in the controlled terminology enum. Without additional context to determine the specific immunoassay type (ELISA, immunohistochemistry, etc.), this remains the most accurate value.\n\n3. **tumorType**: \"NFIB\" \u2192 \"Neurofibroma\" - NFIB is not in the controlled terminology and appears to be an abbreviation or informal term. Narrowed to \"Neurofibroma\", which is the appropriate specific tumor type term from the schema that aligns with neurofibromatosis."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3055,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1491
            }
          }
        },
        "score": 0.3333333333333333,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "immunocytochemistry",
          "tumorType": "Cutaneous Neurofibroma"
        },
        "token_usage": {
          "input_tokens": 3055,
          "output_tokens": 1491,
          "total_tokens": 4546
        }
      },
      {
        "sample_index": 7,
        "input": {
          "diagnosis": "NF",
          "assay": "medical imaging",
          "tumorType": "unknown"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n- **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation to the specific, complete diagnostic term for the most common form of neurofibromatosis\n- **assay**: \"medical imaging\" \u2192 \"conventional MRI\" - Narrowed the broad imaging category to a specific, commonly-used imaging modality in neurofibromatosis research\n- **tumorType**: \"unknown\" \u2192 \"Unknown\" - Corrected the capitalization to match the exact controlled vocabulary value in the Target Schema",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3048,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 764
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01PFkCGsmmAoxurpfPnsFVmp",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Looking at the input data:\n- \"diagnosis\": \"NF\"\n- \"assay\": \"medical imaging\"\n- \"tumorType\": \"unknown\"\n\nI need to narrow these broad terms to more specific terms from the controlled vocabulary in the Target Schema.\n\n1. **diagnosis**: \"NF\" - This is a broad abbreviation that typically stands for \"Neurofibromatosis\". Looking at the enum values, I see \"Neurofibromatosis type 1\" is an option. However, \"NF\" could also refer to NF2-related schwannomatosis or other NF-related conditions. Since \"NF\" most commonly refers to NF1 when used without a number, and \"Neurofibromatosis type 1\" is in the list, that would be the most appropriate narrowing. If we truly don't know which type, \"Unknown\" would be appropriate, but since NF typically refers to NF1, I should narrow it to \"Neurofibromatosis type 1\".\n\n2. **assay**: \"medical imaging\" - This is very broad. Looking at the enum, there are many specific imaging types:\n   - \"conventional MRI\"\n   - \"structural MRI\"\n   - \"functional MRI\"\n   - \"resting state functional MRI\"\n   - \"diffusion MRI\"\n   - \"Magnetization-Prepared Rapid Gradient Echo MRI\"\n   - \"magnetic resonance angiography\"\n   - \"magnetic resonance spectroscopy\"\n   - \"x-ray\"\n   - \"x-ray computed tomography\"\n   - \"ultrasound\"\n   - \"high frequency ultrasound\"\n   - \"positron emission tomography\"\n   - \"optical coherence tomography\"\n   - \"optical tomography\"\n   \n   The most common and general medical imaging technique in NF research is MRI. \"conventional MRI\" would be a reasonable narrowing of \"medical imaging\" as it's one of the most commonly used techniques.\n   \n3. **tumorType**: \"Unknown\" matches the exact enum value, addressing the case-sensitivity issue. This preserves the original uncertainty about the specific tumor type while adhering to the controlled vocabulary.\n\nVerification confirms all three terms align precisely with the schema's controlled vocabulary.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Neurofibromatosis type 1\",\n  \"assay\": \"conventional MRI\",\n  \"tumorType\": \"Unknown\"\n}\n```\n\n**Explanation of corrections:**\n- **diagnosis**: \"NF\" \u2192 \"Neurofibromatosis type 1\" - Narrowed the broad abbreviation to the specific, complete diagnostic term for the most common form of neurofibromatosis\n- **assay**: \"medical imaging\" \u2192 \"conventional MRI\" - Narrowed the broad imaging category to a specific, commonly-used imaging modality in neurofibromatosis research\n- **tumorType**: \"unknown\" \u2192 \"Unknown\" - Corrected the capitalization to match the exact controlled vocabulary value in the Target Schema"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3048,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 764
            }
          }
        },
        "score": 1.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "conventional MRI",
          "tumorType": "Unknown"
        },
        "token_usage": {
          "input_tokens": 3048,
          "output_tokens": 764,
          "total_tokens": 3812
        }
      },
      {
        "sample_index": 8,
        "input": {
          "diagnosis": "neurocristopathy",
          "assay": "transcriptomics",
          "tumorType": "neurolemmoma"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"transcriptomics\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"neurocristopathy\" \u2192 \"Unknown\"\n   - \"Neurocristopathy\" is a very broad term referring to disorders of neural crest-derived tissues, which encompasses multiple conditions in the schema (NF1, NF2, various schwannomatosis types, etc.). Without additional clinical context to determine which specific neurocristopathy is present, \"Unknown\" is the most appropriate value.\n\n2. **assay**: \"transcriptomics\" \u2192 \"transcriptomics\" \n   - This value is already in the controlled terminology and is appropriately specific, so no change was needed.\n\n3. **tumorType**: \"neurolemmoma\" \u2192 \"Schwannoma\"\n   - \"Neurolemmoma\" is a historical/alternative synonym for schwannoma. The controlled terminology uses \"Schwannoma\" as the precise term.",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3056,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1182
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_01NB8KUBuaf1SZLDbY6jUY3i",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad/general terms to more specific ones from the Target Schema:\n\n1. **diagnosis**: \"neurocristopathy\" \n   - Neurocristopathy is a broad term referring to disorders related to neural crest cells\n   - Looking at the enum values, the diseases listed include various schwannomatosis types, Neurofibromatosis type 1, etc.\n   - These are all neurocristopathies (disorders of neural crest-derived cells)\n   - Since the term is very broad and could refer to many conditions in the list, and without more context, the most appropriate narrowing would be to either \"Unknown\" or keep it as one of the general categories\n   - However, since schwannomas and neurofibromas are neural crest-derived tumors, common neurocristopathies include NF1, NF2, and various schwannomatosis types\n   - Without more specific information, I should probably use \"Unknown\" as it's too broad to narrow to a specific condition\n\n   Actually, wait - let me reconsider. The most common neurocristopathies in this context would be:\n   - Neurofibromatosis type 1\n   - NF2-related schwannomatosis\n   - Schwannomatosis\n   \n   Since \"neurocristopathy\" is very broad and encompasses multiple conditions, and we don't have enough context to determine which specific one, \"Unknown\" seems most appropriate.\n\n2. **assay**: \"transcriptomics\"\n   - This is already in the enum list! \"transcriptomics\" is listed as one of the valid values\n   - So this one doesn't need to be changed, it's already specific enough and matches the controlled terminology\n\n3. **tumorType**: \"neurolemmoma\"\n   - Neurolemmoma is an older/alternative term for schwannoma\n   - Looking at the enum, \"Schwannoma\" is listed\n   - So this should be narrowed to \"Schwannoma\"\n   \nConsidering the schwannoma context and transcriptomics assay, I'll refine the diagnosis. Given the specific tumor type, \"Sporadic Schwannoma\" emerges as the most precise diagnosis. The broad \"neurocristopathy\" needs to be replaced with a more targeted classification that aligns with the schwannoma characteristics.\n\nNarrowing the diagnosis requires careful consideration of the available information. \"Schwannomatosis-NOS\" provides a flexible option, capturing the schwannoma nature without overspecifying. If the tumor location is known, \"Vestibular Schwannoma\" could be an even more precise choice.\n\nGiven the limited clinical details, \"Sporadic Schwannoma\" offers a balanced approach - more specific than the broad neurocristopathy category without assuming complex syndrome involvement. Ultimately, \"Unknown\" remains the most prudent designation when definitive context is absent.",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Unknown\",\n  \"assay\": \"transcriptomics\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Explanation of corrections:**\n\n1. **diagnosis**: \"neurocristopathy\" \u2192 \"Unknown\"\n   - \"Neurocristopathy\" is a very broad term referring to disorders of neural crest-derived tissues, which encompasses multiple conditions in the schema (NF1, NF2, various schwannomatosis types, etc.). Without additional clinical context to determine which specific neurocristopathy is present, \"Unknown\" is the most appropriate value.\n\n2. **assay**: \"transcriptomics\" \u2192 \"transcriptomics\" \n   - This value is already in the controlled terminology and is appropriately specific, so no change was needed.\n\n3. **tumorType**: \"neurolemmoma\" \u2192 \"Schwannoma\"\n   - \"Neurolemmoma\" is a historical/alternative synonym for schwannoma. The controlled terminology uses \"Schwannoma\" as the precise term."
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3056,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1182
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "NF2-related schwannomatosis",
          "assay": "RNA-seq",
          "tumorType": "schwannoma"
        },
        "token_usage": {
          "input_tokens": 3056,
          "output_tokens": 1182,
          "total_tokens": 4238
        }
      },
      {
        "sample_index": 9,
        "input": {
          "diagnosis": "phakomatosis",
          "assay": "viability assay",
          "tumorType": "tumor of cranial and spinal nerves"
        },
        "response": {
          "success": true,
          "content": "```json\n{\n  \"diagnosis\": \"Schwannomatosis\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Explanation of narrowing:**\n- **diagnosis**: \"phakomatosis\" (broad term for neurocutaneous syndromes) \u2192 \"Schwannomatosis\" (specific form of phakomatosis characterized by multiple schwannomas)\n- **assay**: \"viability assay\" (general term) \u2192 \"cell viability assay\" (specific standardized assay method)\n- **tumorType**: \"tumor of cranial and spinal nerves\" (anatomical description) \u2192 \"Schwannoma\" (specific tumor type that occurs on cranial and spinal nerves)",
          "model_id": "global.anthropic.claude-sonnet-4-5-20250929-v1:0",
          "usage": {
            "input_tokens": 3060,
            "cache_creation_input_tokens": 0,
            "cache_read_input_tokens": 0,
            "output_tokens": 1179
          },
          "attempt": 1,
          "raw_response": {
            "model": "claude-sonnet-4-5-20250929",
            "id": "msg_bdrk_019fmM2vuEsbZCo9ge9cQ65z",
            "type": "message",
            "role": "assistant",
            "content": [
              {
                "type": "thinking",
                "thinking": "Let me analyze the input data and narrow the broad terms to more specific ones from the Target Schema.\n\nInput:\n1. \"diagnosis\": \"phakomatosis\" - This is a broad term referring to neurocutaneous disorders\n2. \"assay\": \"viability assay\" - This is a broad term for cell viability testing\n3. \"tumorType\": \"tumor of cranial and spinal nerves\" - This is a broad term for nerve tumors\n\nLooking at the Target Schema enums:\n\nFor \"diagnosis\":\n\"phakomatosis\" is a broad term that refers to a group of neurocutaneous syndromes. In the context of the schema, which includes conditions like Neurofibromatosis type 1, NF2-related schwannomatosis, various schwannomatosis types, etc., \"phakomatosis\" could be narrowed to specific conditions. However, without more context, I should look for the most general appropriate term. Looking at the options:\n- \"Neurofibromatosis type 1\" - a specific phakomatosis\n- \"NF2-related schwannomatosis\" - a specific type\n- \"Schwannomatosis-NOS\" - NOS means \"Not Otherwise Specified\"\n- \"Unknown\"\n\n\"Phakomatosis\" is a broad term that includes NF1, NF2, and other neurocutaneous disorders. Since we don't have specific information, \"Schwannomatosis-NOS\" (Not Otherwise Specified) might be appropriate, or it could remain at a general level. However, looking more carefully at the available options, there isn't a perfect match for a general \"phakomatosis.\" The closest might be one of the specific conditions. Given the context of this schema focusing on neurofibromatosis and schwannomatosis conditions, I should pick the most appropriate narrow term.\n\nActually, \"Neurofibromatosis type 1\" is one of the most common phakomatoses in this context.\n\nFor \"assay\":\n",
                "signature": "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"
              },
              {
                "type": "text",
                "text": "```json\n{\n  \"diagnosis\": \"Schwannomatosis\",\n  \"assay\": \"cell viability assay\",\n  \"tumorType\": \"Schwannoma\"\n}\n```\n\n**Explanation of narrowing:**\n- **diagnosis**: \"phakomatosis\" (broad term for neurocutaneous syndromes) \u2192 \"Schwannomatosis\" (specific form of phakomatosis characterized by multiple schwannomas)\n- **assay**: \"viability assay\" (general term) \u2192 \"cell viability assay\" (specific standardized assay method)\n- **tumorType**: \"tumor of cranial and spinal nerves\" (anatomical description) \u2192 \"Schwannoma\" (specific tumor type that occurs on cranial and spinal nerves)"
              }
            ],
            "stop_reason": "end_turn",
            "stop_sequence": null,
            "usage": {
              "input_tokens": 3060,
              "cache_creation_input_tokens": 0,
              "cache_read_input_tokens": 0,
              "output_tokens": 1179
            }
          }
        },
        "score": 0.0,
        "ground_truth": {
          "diagnosis": "Neurofibromatosis type 1",
          "assay": "3D microtissue viability",
          "tumorType": "Malignant Peripheral Nerve Sheath Tumor"
        },
        "token_usage": {
          "input_tokens": 3060,
          "output_tokens": 1179,
          "total_tokens": 4239
        }
      }
    ],
    "metrics": {
      "total_samples": 10,
      "successful_runs": 10,
      "failed_runs": 0,
      "success_rate": 1.0,
      "average_score": 0.4,
      "min_score": 0.0,
      "max_score": 1.0,
      "num_scored": 10
    },
    "duration_seconds": 200.9650583267212,
    "token_usage": {
      "input_tokens": 30562,
      "output_tokens": 11957,
      "total_tokens": 42519
    }
  }
}